Dermal and Ophthalmological Acceptability Assessment in Sensitive Skin

This is a single-center, single-blind clinical study designed to evaluate the safety of the investigational product through dermatological and ophthalmological clinical assessments. A total of 33 female participants, aged 18 to 60 years, with a clinical diagnosis of sensitive skin confirmed by the Stinging Test, will be enrolled. Safety evaluations will be performed throughout the study period using standardized clinical assessments.

Inclusion Criteria: * Female participants aged 18 to 60 years. * Participants with any skin type, with at least 25% representation of each skin type. * Participants with sensitive skin, clinically confirmed by the Stinging Test. * Intact skin in the assessment area. * Willingness to comply with all study procedures and attend scheduled visits and assessments. * Ability to understand, provide written informed consent, and sign the Informed Consent Form (ICF). Exclusion Criteria: * Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study. * Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening. * Skin marks or conditions in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn. * History of atopic disease or allergy to cosmetic products. * Active skin diseases and/or lesions in the assessment area or elsewhere on the body. * Immunosuppression due to medication use or active disease. * Uncontrolled endocrine disorders. * Relevant medical history or current evidence of alcohol or drug abuse. * Known history or suspected intolerance to products of the same category as the investigational product. * Intense sun exposure within 15 days prior to assessment. * Aesthetic or dermatological treatments within 4 weeks prior to assessment. * Any other condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record. * Participants with entropion, ectropion, hordeolum (stye), conjunctivitis, uveitis, or other active ocular diseases at screening. * Participants with corneal ulceration, blepharitis, meibomitis, pterygium, trichiasis, distichiasis, or other moderate to severe ocular disorders. * Initiation of contact lens use within 1 week prior to screening. * Use of ophthalmic products, including eye drops and/or ophthalmic ointments, within 3 weeks prior to screening. * Any other ocular condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.